Table 1 The current observed population receiving MEP
From: The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials
SD or percentage | ||
|---|---|---|
Number of patients | 65 | – |
Female/Male | 29/36 | 45% female |
Age range | 19–84 | – |
Age mean | 56 | ±11.5 |
Current smoker | 17 | 26% |
Duration of asthma (years) | 18.2 | ± 14.4 |
Historical eosinophilic count | 1046 | ± 885 |
Blood eosinophil count at baseline | 653 | ±381 |
Mean exacerbations previous12 months | 3.0 | ±1.8 |
Hospitalized patients previous 12 months | 20 | 31% |
Mean OCS dose at baseline (mg) | 9.2 | ±9.2 |
Mean FEV1 at baseline (%) | 73 | ±18.1 |
ACT | 16.6 | ±4.7 |
Concomitant nasal polyposis | 47 | 72% |